Sysmex (6869) investor relations material

Business overview and market position

• Holds the top global market share in hematology, hemostasis, and urinalysis, with over 50% share in hematology and sales in more than 190 countries and regions.

• Net sales grew from ¥410.5 billion in FY2023 to ¥508.6 billion in FY2025, with an operating margin of 17.2% and overseas sales ratio of 86.7%.

• Business model relies on ongoing sales of reagents, services, and support, accounting for about 70% of revenue, ensuring stable, long-term earnings.

• Products are used in hospitals, clinics, and commercial labs, supporting a global IVD market valued at approximately ¥12.2 trillion.

• Direct sales and service networks have expanded globally, especially in Europe, the US, China, and emerging markets.

Corporate philosophy and customer value

• Philosophy centers on "Three Aspects of Confidence"—customers, business partners, and employees.

• Mission is to shape the advancement of healthcare, emphasizing quality, innovation, and stakeholder trust (anshin).

• Focus on high-quality, robust, and automated products, with scientific support and uninterrupted service.

• Initiatives include improving healthcare accessibility, early disease diagnosis, and supporting fair sports management.

Growth strategy and future initiatives

• Growth strategy targets reinforcement of existing businesses, expansion in emerging countries, and new business development.

• Entered a global OEM agreement with Siemens in hemostasis, aiming to double the target market and leverage hematology channels.

• Expanding blood-based testing for Alzheimer's disease and increasing presence in immunochemistry.

• Proactive initiatives in India and Brazil include new production bases and training centers to capture emerging market growth.

• New business areas include medical robotics (hinotori surgical system), regenerative medicine, and digital healthcare solutions.